CSL Limited (ASX: CSL) - Share Price and Research
Current share price for CSL : $276.430 1.06 (0.38%)+
CSL Limited (CSL), an ASX-listed company, is a global biotechnology company engaged in research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines. CSL's operating model is based around four key value creation activities: early-stage research, product translation, manufacturing, and patient access. CSL's commercial and functional areas operate globally.
Intelligent Investor Australian Equity Income Fund (ASX:INIF), Intelligent Investor Ethical Share Fund (ASX:INES), Intelligent Investor Australian Equity Growth Fund (ASX:IIGF)
owns shares in CSL Limited (ASX: CSL)
CSL General Information +
| ASX Code | CSL |
| Website | http://www.csl.com.au |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 133,849 |
| CSL Share Price |
$276.430 |
| Day High | $277.180 |
| Day Low | $275.520 |
| Last Close | $275.370 |
| CSL Share Price Movement |
$1.06 ( 0.38% ) |
Recommendation
CSL Related Research
CSL Limited (CSL) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| HFResult | $2.17 | 0% | 9 Sep 2024 | 2 Oct 2024 | $276.430 | $272.000 | 1.42% |
| Result | $1.80 | 0% | 11 Mar 2024 | 3 Apr 2024 | $276.430 | $272.000 | 1.42% |
| HFResult | $2.01 | 10% | 11 Sep 2023 | 4 Oct 2023 | $276.430 | $272.000 | 1.42% |
See all dividends from CSL Limited (CSL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
CSL Limited (CSL) price-sensitive announcements
13 Aug 2024 | 8:06 AM
13 Aug 2024 | 8:05 AM
13 Aug 2024 | 8:04 AM
13 Feb 2024 | 8:29 AM
See more price-sensitive ASX announcements or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
CSL Limited (CSL) Recent ASX Announcements
CSL Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026F | $5,692.27 | $1,172.70 | 14.40% | 23.48 | 516.08 | 1.87% | 0.0% |
| 2025F | $4,974.44 | $1,024.81 | 15.10% | 26.87 | 451.14 | 1.64% | 0.0% |
| 2024A | $4,318.18 | $889.99 | 11.10% | 30.63 | 392.16 | 1.44% | 0.0% |
CSL Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
2024 A |
2025 F |
2026 F |
2024 A |
2025 F |
2026 F |
2024 A |
2025 F |
2026 F |
||
|
CSL (CSL) |
$135,786M | 0.2288 | 0.0099 | 0.1497 | 33.4012 | 33.0735 | 28.7665 | 1.42% | 1.32% | 1.49% |
|
Clinuvel Pharmaceuticals (CUV) |
$606M | 0.1810 | 0.0153 | 0.1195 | 17.3352 | 17.0735 | 15.2508 | 0.41% | 0.58% | 0.66% |
|
Mesoblast (MSB) |
$4,028M | -0.3176 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
|
Opthea (OPT) |
$1,404M | 0.2355 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
|
Telix Pharmaceuticals (TLX) |
$9,821M | -1.0561 | 9.7660 | 0.5904 | 1,560.6383 | 144.9605 | 91.1463 | 0.00% | 0.00% | 0.00% |
CSL Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 1.13 | 32.60 | 5.08 | 4.20 |
| Market | 0.66 | 18.50 | 1.40 | 1.11 |
| Sector | 1.13 | 21.00 | 2.23 | 1.40 |
CSL Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Paul McKenzie | Chief Operating Officer, Executive Director, Chief Executive Officer, Managing Director | 13 Dec 2022 |
| Ms Carolyn Judith Hewson | Non-Executive Director | 9 Dec 2019 |
| Ms Alison Mary Watkins | Non-Executive Director | 18 Aug 2021 |
| Dr Robert Andrew Cuthbertson | Non-Executive Director | 17 Oct 2018 |
| Ms Marie Elizabeth McDonald | Non-Executive Director | 14 Aug 2013 |
| Ms Samantha (Sam) Louise Lewis | Non-Executive Director | 1 Jan 2024 |
| Dr Megan Elizabeth Clark | Non-Executive Director | 16 Feb 2016 |
| Ms Elaine Sorg | Non-Executive Director | 1 Sep 2024 |
| Dr Brian Daniels | Non-Executive Director | 1 Dec 2024 |
| Dr Brian Anthony McNamee | Non-Executive Director, Non-Executive Chairman | 13 Feb 2018 |
CSL Limited (CSL) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 31 Oct 2024 | MCKENZIE, Paul | Sell | Indirect Shares | 4,000 | $287.150 | $1,148,600.000 |
| 3 Sep 2024 | MCKENZIE, Paul | Sell | Indirect Shares | 3,779 | $304.313 | $1,149,997.110 |
| 21 Aug 2024 | WATKINS, Alison | Issued | Related Securities | 308 | $304.080 | $93,656.640 |
See all changes in directors' interest & trades for CSL Limited (CSL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
CSL Management
| Name | Position |
|---|---|
| Kate Priestman | Chief Corporate & External Affairs Officer |
| Joy Linton | Chief Financial Officer |
| Roanne Parry | Chief Human Resources Officer |
| Fiona Mead | Company Secretary,Head of Group Governance |
| Ken Lim | Executive Vice President and Chief Strategy Officer |
| Mark Hill | Executive Vice President, Chief Digital Information Officer |
| Andy Schmeltz | Executive Vice President, CSL Behring |
| Bill Mezzanotte | Executive Vice President, Head of Research & Development |
| Greg Boss | Executive Vice President, Legal and CSL Group General Counsel |
| Dave Ross | Senior Vice President and General Manager CSL Seqirus |
| Herve Gisserot | Senior Vice President and General Manager CSL Vifor |
CSL Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in CSL Limited (CSL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names.
These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 29,225,168 (6.04%) | State Street Corporation and subsidiaries |
| 27,353,205 (5.66%) | BlackRock Group |
CSL Calendar of Events
| Date | Event |
|---|---|
| 12 August 2025 | Report (Prelim) |
| 11 February 2025 | Report (Interim) |
FAQs about CSL Limited (CSL)
CSL Limited's (CSL) current share price is $276.43. This constitutes a price movement of 1.63% when compared to the share price 7 days ago and is -11.44% below CSL's 12-month high of $312.15 per share. Prices are delayed by at least 20 minutes.
Relative to the previous close share price of $275.37, CSL Limited's (CSL) current share price of $276.43 constitutes a movement of $1.06 or 0.38%. CSL Limited's (CSL) share price movement is 1.63% when compared to 7 days ago and is -11.44% below CSL's 52-week high of $312.15.
CSL Limited's (CSL) 52-week high is $312.15 which was reached on 23 Jul 2024. Relative to this, CSL's current share price of $276.43 constitutes a -$35.72 or -11.44% drop since that high of $312.15 per CSL share.
CSL Limited's (CSL) 52-week low is $269.49 which was reached on 19 Apr 2024. Relative to this, CSL's current share price of $276.43 constitutes a $6.94 or 2.58% gain since that low of $269.49 per CSL share.
Over the last 12 months, CSL Limited (CSL) has a daily average trading volume of 643,039 CSL shares per day.
CSL Limited (CSL) has a current dividend yield of n/a this year. Last year's dividend yield was 1.40%. The dividend yield for CSL is a ratio that tells you the percentage of CSL Limited's (CSL) share price that it pays out in dividends each year.
CSL Limited (CSL) last dividend payment was $2.17 per share and was paid on 2 Oct 2024. This last CSL dividend included 0% franking.
CSL Limited (CSL) has a franking level of 0%. Franking represents the tax CSL Limited (CSL) has already paid on any profit it distributes to shareholders as a dividend.
CSL Limited (CSL) will release its next Annual Report on n/a. CSL Limited's (CSL) last annual report was released on 2 Sep 2022. Click here to view CSL Limited's (CSL) last annual report.
CSL Limited (CSL) is classified as Health Care. Other companies in this sector include
ResMed Inc. (RMD),
Pro Medicus Limited (PME),
Cochlear Limited (COH), and
Fisher & Paykel Healthcare Corporation Limited (FPH).
The price-to-earnings (P/E) ratio for CSL Limited (CSL) is 32.6. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of CSL Limited's (CSL) share price to its earnings per CSL share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
Proudly
Call 1300 880 160
